The Latest Breaking News from CARA

Cara Therapeutics Inc (NASDAQ:CARA) announced topline results from its Phase 2 proof-of-concept trial (KOMFORT) of difelikefalin for moderate-to-severe pruritus in patients with notalgia paresthetica, a nerve disorder characterized by chronic pruritus (itchy skin) of the upper to middle back. The primary efficacy endpoint was the change from baseline in the weekly mean of…

Newcastle University is increasing its support for students and colleagues escaping war or at risk of persecution

Cara Therapeutics Inc (NASDAQ: CARA) 

The cannabis market is growing significantly due to cannabis’ proven medical usage and the legalization of its recreational use in several parts of the world. The legalization movement is expected to grow stronger in the coming years. Thus, we believe cannabis stocks Cara Therapeutics (CARA) and Valens (VLNS) could be…

Adoption practices in India are primarily informed by the Hindu Adoption and Maintenance Act, 1956 (HAMA) and Juvenile Justice (Care and Protection of Children) Act, 2000 (JJ Act).

Benzinga Pro data, Cara Therapeutics (NASDAQ:CARA) reported Q4 sales of $821.00 thousand. Earnings fell to a loss of $33.38 million, resulting in a 3195.36% decrease from last quarter.

Cara Therapeutics, Inc. (NASDAQ: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced financial results and operational highlights for the fourth quarter and full year ended December 31, 2021.

Cara Therapeutics (NASDAQ:CARA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement.

Cara Therapeutics, (NASDAQ:CARA) known for its research on cannabinoid receptor agonists for the relief of inflammatory and neuropathic pain, will host a virtual research and development event on Friday, March 11 from 1:00 to 2:00 p.m.